Thursday, December 3, 2020
Home Latest Pharma-News Single, subanesthetic-dose of ketamine infusion relatively free of side effects for...

Single, subanesthetic-dose of ketamine infusion relatively free of side effects for patients with treatment-resistant depression

Nov 15, 2019: NIH researchers found that a single, subanesthetic-dose of ketamine infusion was relatively free of side effects for patients with treatment-resistant depression symptoms within hours in people who have not responded to conventional antidepressants, which typically take weeks or months to work. No drug-related serious adverse events or increased ketamine cravings with a single-administration.”“side effect of ketamine infusion found like feeling strange or loopy, difficulty speaking, visual distortions,” most side effects peaked within an hour of ketamine administration and were gone within two hours.  https://www.nih.gov/news-events/news-releases/side-effects-mild-brief-single-antidepressant-dose-intravenous-ketamine

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

4 × 5 =

Most Popular

FDA approves Xolair® (omalizumab) for adults with nasal polyps

December 01, 2020: "Roche announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application (sBLA)...

UK authorises Pfizer/BioNTech COVID-19 vaccine

December 02, 2020: "A Department of Health and Social Care spokesperson said: The government has accepted the recommendation from...

WHO Releases COVID-19 App for Trusted and Timely Updates

 December 01, 2020: The WHO has published a new mobile app to centralize the most trusted updates about COVID-19, and to guide...